A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

October 4, 2021

Study Completion Date

October 12, 2021

Conditions
Chronic PruritusAtopic Dermatitis
Interventions
DRUG

BLU-5937

Oral administration of BLU-5937 tablets

DRUG

Placebo

Oral administration of matching placebo for BLU-5937 tablets

Trial Locations (33)

10075

Bellus Health Investigational Site #34, New York

19073

Bellus Health Investigational Site #37, Newtown Square

27262

Bellus Health Investigational Site #14, High Point

31406

Bellus Health Investigational Site #24, Savannah

33012

Bellus Health Investigational Site #15, Hialeah

33063

Bellus Health Investigational Site #32, Margate

33125

Bellus Health Investigational Site #16, Miami

33136

Bellus Health Investigational Site #19, Miami

33172

Bellus Health Investigational Site #17, Sweetwater

42301

Bellus Health Investigational Site #13, Owensboro

55402

Bellus Health Investigational Site #36, Minneapolis

57702

Bellus Health Investigational Site #41, Rapid City

70115

Bellus Health Investigational Site #18, New Orleans

70433

Bellus Health Investigational Site #45, Covington

70809

Bellus Health Investigational Site #38, Baton Rouge

73071

Bellus Health Investigational Site #29, Norman

77845

Bellus Health Investigational Site #31, College Station

78213

Bellus Health Investigational Site #40, San Antonio

78229

Bellus Health Investigational Site #11, San Antonio

78759

Bellus Health Investigational Site #12, Austin

85032

Bellus Health Investigational Site #28, Phoenix

85254

Bellus Health Investigational Site #10, Scottsdale

90212

Bellus Health Investigational Site #23, Beverly Hills

92024

Bellus Health Investigational Site #33, Encinitas

92123

Bellus Health Investigational Site #35, San Diego

92708

Bellus Health Investigational Site #27, Fountain Valley

98101

Bellus Health Investigational Site #25, Seattle

03801

Bellus Health Investigational Site #22, Portsmouth

G7H 7Y8

Bellus Health Investigational Site #44, Chicoutimi

H2X 2V1

Bellus Health Investigational Site #20, Montreal

G1N 4V3

Bellus Health Investigational Site #43, Québec

G1W 4R4

Bellus Health Investigational Site #39, Québec

J1L 0H8

Bellus Health Investigational Site #42, Sherbrooke

All Listed Sponsors
lead

Bellus Health Inc. - a GSK company

INDUSTRY

NCT04693195 - A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis | Biotech Hunter | Biotech Hunter